Dougherty's Pharmacy, Dallas, TX

Is Dougherty's Pharmacy registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Dougherty's Pharmacy hold a Texas pharmacy license?

The Texas State Board of Pharmacy lists license 3246 for DOUGHERTY'S PHARMACY, DALLAS, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7251 for Dougherty's Pharmacy, Dallas, TX, status Expired, as of Nov 15, 2026.

Has Dougherty's Pharmacy had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (May 14, 2020), 1 state referral letter (May 18, 2020) and 1 FMD-145 letter (May 18, 2020) for Dougherty's Pharmacy. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 marks prior disciplinary orders on license 3246 (column DISP ACTN, value Y); the orders themselves are on the board’s license lookup and are not copied here. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Dougherty's Pharmacy
Location
Dallas, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 18, 2020
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 12 observations
State board records
License found: 3246, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Dougherty's Pharmacy, a 503A facility, with 4 dated actions.

Document
May 18, 2020FMD-145 letterFMD-145 Letter Issued 05/18/2020FDA copy (archived)
May 18, 2020State referral letterReferral Letter to the Texas State Board of Pharmacy Issued 05/18/2020FDA copy (archived)
May 14, 2020Warning letter close-outWarning Letter Closeout Issued 05/14/2020Not linked by FDA
Jul 1, 2019Form 483483 Issued 07/01/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Dougherty's Pharmacy, Dallas, TX (FEI number 1000371043), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jul 1, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)10003710431094813
Dec 29, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)1000371043954302

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 12 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Dec 8, 2015 to Dec 29, 2015: 12 observations

Firm on the cover
FEI number
1000371043
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

A La ck of sterility testing for sterile pro ducts produced from 6/2015 to 9/2015. From 6/1/2015 to 9/13/2015 your fi

rm produced and released approximatel y redacted b4 lots of product containing Alprostadil USP (Prostaglandin EI) (PGE)(a non-sterile redacted b4 to sterile product) without performing sterility testing.

B St erile to ster ile products were redacted b4 and tested for sterility using an in-house sterility test m ethod that has not been validated. C La ck of endotoxin testing for non-sterile to sterile products produced from 6/1/2015 to date.

D Pe r your logged formula worksheets non-sterile products are issued extended beyond use dates (BUDs), these p

tween redacte d b4 with 90 days BUD according to the logged formula worksheets.

A F or e xample the following products containing PGE (a non-sterile redacted b4) were released be

roducts lack sterility testing and verification of sterility.

Observation 2

Written records are not made of investigations into unexplained discrepancies.

Specifically,

During the redacted

b4 certification of your firm’s ISO 7 redacted b4 conducted on redacted b4, the viable air was sampled redacted b4. Four out of redacted b4 tested air samples (air sample # redacted b4 and redacted b4 yielded a “failed” result. The total viable air CFU result exceeded the action level concentration of redacted b4 for air sample # redacted b4 and # redacted b4 while actionable microorganisms were detected in air sample # redacted b4 and # redacted b4 as follows:Durin

Duri ng th e red acted b4 certification of your firm’s ISO 7 redacted b4 conducted on redacted b4, the viable air was sampled redacted b4. Four out of redacted b4 tested air samples (air sample # redacted b4 and redacted b4 yielded a “failed” result. The total viable air CFU result exceeded the action level concentration of redacted b4 for air sample # redacted b4 and # redacted b4 while actionable microorganisms were detected in air sample # redacted b4 and # redacted b4 as follows: ...

Read the full 483 (PDF on fda.gov)

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. Your firm failed to conduct environmental monitoring of air, personnel and surface during daily production periods, within the JSO 7 cleanroom and ISO 5 LFH used to prepare your sterile drug products.

a Du ring the period covering June 2015 to December 2015, no environmental monitoring of air, perso nnel, or surface was performed by your firm. During this period, an average number of redacted b4 sterile drug product formulations were manipulated, filled and distribution form you facility per day . B there are redacted b4 iso 5 redacted b4 Laminar air flow hoot (LEH) redacted b4 located within the ISO 7 areas. These redacted b4 ISO 5 redacted b4. However, your firm only performs environmental monitoring of these iso 5 redacted b4. B there ar e redacted b4 iso 5 redacted b 4 Lamina r air flow hoot (LEH) redacted b4 located within the ISO 7 areas. These redacted b4 ISO 5 redacted b4. However, your firm only performs environmental monitoring of these iso 5 redacted b4. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength , quality and purity at the time ofuse.

Specifically,

Revie w of yo ur firms logged formula worksheets from 6/2015 to 12/2015 showed that drug products are produ

ced into redacted b4 and given redacted b4 these redacted b4. No potency and impurity testing performed to ensure these drug products continue to meet the applicable standards of identity, strength, quality, and purity. Furthermore, no stability testing or data has been performed.

A bulk re

A bu lk redacted b4 alprostadil USP (prostaglandin El redacted b4 is used to produce the following redacted b4

A bulk redacted b4 alprosta dil USP (prostaglandin El redacted b4 is used to produce the following redacted b4

dacted b4 alprostadil USP (prostaglandin El redacted b4 is used to produce the following redacted b4

A redacted b4 alprostadil (PF) redacted b4. Production date redacted b4: redacted b4 PGE redacted b4

1 PGE redacted b4 Production date redacted b4 Lot number: redacted b4

1 P GE redacted b4 Production date redacted b4 Lot number: redacted b4 ...

Read the full 483 (PDF on fda.gov)

Observation 5

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and stre ngth of each active ingredient prior to release.

Specifica lly,

A Yo ur firm fa iled to conduct potency testing of your sterile finished products at the time of release. Fr om june 2015 to

December 8 2015, your firm prod uced and distributed about redacted b4 batches of sterile drug products. Out of the redacted b4 batches distributed redacted b4 had extended beyond use date (bud) of 90-180 days. The drug products were not tested for potency to ascertain that the suitability throughout the bud. 111 A Your firm failed to co nduct potency testing of your sterile fini shed products at the time of release. From june 2015 to December 8 2015, your firm produced and distributed about redacted b4 batches of sterile drug products. Out of the redacted b4 batches distributed redacted b4 had extended beyond use date (bud) of 90-180 days. The drug products were not tested for potency to ascertain that the suitability throughout the bud. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Laboratory controls do not include the establishment ofscientifically sound and appropriate test procedures designed to

assure that drug product containers conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your finn's product inspection process is deficient in that you do not perform 100% visual checks, against a contrasting background ofyour sterile liquid fonnu lations prior to release. According to the "Compounding" Manager, abou- ofthe fmished products are visually inspected. Additionally, your fmn has nor established a written procedure for performing visual checks within products.

Observation 7

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established, written, and followed.

for the re dacted b4 in the iso 7 buffer room directly in front of a return air vent located o n the base of the wall next to the rear of the ISO 5 redacted b laminar air flow hood (LFH). We also observed a chair with an approximate 3” diameter silver color metal base being placed directly in front of the return air vent located on the base of the wall in the iso 7 buffer room next to the front of the iso 5 LDF. This chair is only positioned in this location during drug manipulation activates. The certification of your iso 7 buffer room and the so LFH was not done during drug manipulation activates. Furthermore, there is an approximately two 92) feet by four (4) feet silver shelving unit with cleaning and growing material stored in front fo the return air vents in the iso 7 gowning/preparation room. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Clothing of personnel engaged in the manu facturing and holding ofdrug products is not appropriate for the duties they perform.

Specifically,

A on 12/8/2015, we observed your technicians during aseptic processing of sterile human drugs inside the iso 7 b

uffer room and iso 5 redactedb4 laminar air flow hood (lfh), wearing non-sterile gown and non-sterile hair

Nets. We observed this practice during the production and filling of the following sterile drug products.

B on 12 /8/2015, the technicians had their forehead, eyes, and neck region exposed during aseptic processing ( manipulations and filling) of sterile human drugs ( pilocarpine; re dacted b4). During the perform ance of this sterile operation, they had their foreheads inside the iso 5 lfh where there was no phys ical barrier between their exposed skin and non-sterile gowning materia ls and the open pilocarp ine redacted b4 devices on the lfh work surface. During thi s time we observed that gowning for sterile operation is inadequate in that

A. Employees wore non-sterile gowns, hair nets, and shoe covers during aseptic processing ofsterile drug production in the ISO 5 LFH.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Equipment used in the manufacture, processing, packing or holding ofdrug products is no t ofappropriate design to faci litate operations for its intended use .

Specifically,

A t he firm has not conducted equipment qualification to show that redacted b4 and redacted b4 used to sterilize and depyrogenate glassware achieve appropriate log reduction of microbes. The firm does not use any redacted b4 during the sterilization of glassware and liquid suspensions. Furthermore, the firm failed to conduct temperature mapping studies of refrigerators and freezers used to store finished compounded drugs and redacted b4

A th e firm has not conducted equipment qualification to show that redacted b4 and redacted b4 used to sterilize and depyrogenate glassware achieve appropriate log reduction of microbes. The firm does not use any redacted b4 during the sterilization of glassware and liquid suspensions. ...

Read the full 483 (PDF on fda.gov)

Observation 10

The distribution system is deficient in that eac b lot of drug product cannot be readily determined to facilitate its recall if

necessary.

Specifically,

Finished products are issued lot numbers re dacted b4. The prescription labels do not contain the redacted b4. Per the “compounding” manager, the only way to know what redacted b4 however, review of your logged formula worksheets and provided labels shows that not all redacted b4 for example:

Observation 11

Aseptic processing areas are deficient regarding the system for cleaning and d isinfecting the room and equjpment to produce aseptic conditions.

Specifically,

A yo ur firm pr oduces an average of redacted b4 batches of sterile drug products using iso 7 cleanrooms and iso 5 redacted b4 laminar air flow hood (lfh). Your firm us es redacted b4 sporicidal agent during the reda cted b4 cleaning and sanitization of the iso 5 lfh and iso 7 cleanroom. B yo ur firm fail ed to conduct a disinfectant efficacy studies involving the redacted b4 sporicide and other disinf

ectants in use at the facility. In addition, there is no defined and establishe d contact time and freque ncy of use for the disinfectants.

Observation 12

Complaint procedures are deficient in that written complaint records are not maintained in a file designated for drug product

complaints.

Specifically,

Per your firm 's "Compounding" Manager your firm does not keep records ofdrug product co mplaints.

Linked 483s whose text is not shown

State board of pharmacy records

The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatusPrior disciplinary orders (file flag)
3246Community Sterile CompoundingDOUGHERTY'S PHARMACYDALLASActiveYes

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 7251OSPDougherty's PharmacyDallas, TXExpired

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.